Immunology:
Our other therapy areas

    • {%itemName%}
        {%brandMenuItems%}
    • {%itemName%} {%arrowSpan%}
        {%subBrandMenuItems%}
    • {%itemName%} {%arrowSpan%}
        {%productMenuItems%}
    • {%itemKeyName%} {%itemBadges%} {%arrowSpan%}
      {%selfProduct%}
    • {%itemName%}
      • {%countries%}
    • {%allMenuItem%}
      • {%languages%}

      • This website is for UK Healthcare Professionals only

      UK-RNQD-220313. Date of Prep: December 2022.

      OBJECTIVE: TO EVALUATE THE EFFICACY AND SAFETY OF RINVOQ MONOTHERAPY FOR THE TREATMENT OF ADOLESCENT (12 years and older) AND ADULT SUBJECTS WITH MODERATE TO SEVERE AD WHO ARE CANDIDATES FOR SYSTEMIC THERAPY2,3

      These studies were only vs placebo and were not designed to compare the RINVOQ 15 mg and 30 mg doses against each other

      Adpated from Guttman-Yassky, et al.2

      *TCS were permitted during the blinded extension period and were not counted as rescue therapy. 
      †30-day follow up.

      AD, atopic dermatitis; BID, twice daily; BL, baseline; EASI, Eczema Area and Severity Index; EASI 75, ≥75% reduction in EASI; ITT, intention-to-treat; NRI-C, nonresponder imputation incorporating Multiple Imputation to handle missing data due to COVID-19; OC, observed cases; OD, once daily; R, randomised; RIN, RINVOQ; TCS, topical corticosteroids; vIGA-AD, Validated Investigator's Global Assessment for atopic dermatitis.

       

      Adpated from Guttman-Yassky, et al.2

      aBody weight ≥40 kg at BL for subjects ≥12 and <18 yrs; bDiagnosis of AD according to the Hanifin and Rajka criteria (≥3 of 4 major features and ≥3 of 23 minor features); cor for patients for whom topical treatments were otherwise medically inadvisable; dexception of topical emollients; elaser therapy, tanning booth, or extended sun exposure that could affect disease severity or interfere with disease assessments; fOral or parenteral; gwithin 4  weeks or five half-lives of the drug (whichever is longer) or is currently enrolled in another clinical study.

      AD, atopic dermatitis; ADERM-IS, Atopic Dermatitis Impact Scale; ADERM-SS, Atopic Dermatitis Symptom Scale; BL, baseline; BSA, body surface area; DLQI, Dermatology Life Quality Index; EASI, Eczema Area and Severity Index; EASI 75, ≥75% reduction in EASI; EASI 90, ≥90% reduction in EASI; EASI 100, 100% reduction in EASI; HADS, Hospital Anxiety and Depression Scale; IGA, Investigator’s Global Assessment; JAK, Janus kinase; NRS, numerical rating scale; POEM, patient-oriented Eczema Measure; RIN, RINVOQ; SCORAD, scoring of atopic dermatitis; TCI, topical calcineurin inhibitor; TCS, topical corticosteroids; WP-NRS, Worst Pruritus NRS.

      Adpated from Guttman-Yassky, et al.2

      aNo patients were discontinued for COVID-19 infection or logistical restrictions. bIncludes protocol-mandated discontinuation because of 25% worsening of EASI and other reasons.

      AE, adverse event; EASI, Eczema Area and Severity Index; RIN, RINVOQ. 

      Adpated from Guttman-Yassky, et al.2

      Based on ITT Population. Calculations are based on non-missing records.

      aBased on weekly average.

      BMI, body mass index; BSA, body surface area; DLQI, Dermatology Life Quality Index; EASI, Eczema Area and Severity Index; ITT, intention-to-treat; NRS, numerical rating scale; POEM, Patient-orientated Eczema Measure; RIN, RINVOQ; SD, standard deviation; vIGA-AD, Validated Investigator's Global Assessment for atopic dermatitis.

      Graph adapted from Simpson EL, et al.3

      AD, Atopic dermatitis; EASI, Eczema Area and Severity Index; EASI 75, ≥75% reduction in EASI; EASI 90, ≥90% reduction in EASI; EASI 100, 100% reduction in EASI; ITT, Intention-to-treat; NRI-C, Nonresponder imputation incorporating Multiple Imputation to handle missing data due to COVID-19; OC, Observed cases; OD, Once daily; RCT, Randomised controlled trial;  TCS, Topical corticosteroids; vIGA-AD, Validated Investigator's Global Assessment for atopic dermatitis

      Graph adapted from Simpson EL, et al.3

      AD, Atopic dermatitis; EASI, Eczema Area and Severity Index; EASI 75, ≥75% reduction in EASI; EASI 90, ≥90% reduction in EASI; EASI 100, 100% reduction in EASI; ITT, Intention-to-treat; NRI-C, Nonresponder imputation incorporating Multiple Imputation to handle missing data due to COVID-19; OC, Observed cases; OD, Once daily; RCT, Randomised controlled trial; TCS, Topical corticosteroids; vIGA-AD, Validated Investigator's Global Assessment for atopic dermatitis

      Graph adapted from Simpson EL, et al.3

      Itch reduction (≥4 point improvement in Worst Pruritus NRS from baseline assessed in patients with Worst Pruritus NRS ≥4 at baseline) at Day 1 & 2 for RINVOQ 30 mg and 15 mg, respectively, and at Week 16 for both doses were ranked secondary endpoints.2,3

      1. RINVOQ Summary of Product Characteristics.
      2. Guttman-Yassky E, Teixeira HD, Simpson EL, et al. Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials. Lancet. 2021;397(10290):2151–2168.
      3. Simpson EL, Papp KA, Blauvelt A, et al. Efficacy and Safety of Upadacitinib in Patients With Atopic Dermatitis: Results Through Week 52 From Replicate, Phase 3, Randomized, Double-Blind, Placebo-Controlled Studies: Measure Up 1 and Measure Up 2. Poster presented at the 2021 Dermatology Education Foundation (DEF) Essential Resource Meeting (DERM2021), August 5–8, 2021, Las Vegas NV, USA

      UK-RNQD-220317. Date of preparation: December 2022

      Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk or via the MHRA Yellow Card app, available in the Google Play or Apple App Stores. 
      Adverse events should also be reported to AbbVie on [email protected]